Continuous, Preclinical Activity Reconstruction in 177Lu-based Radiopharmaceutical Therapy Using a Sparse Uncollimated γ-Sensor Network

177Lu-based radiopharmaceutical therapy (RPT) has shown increasing promise in the treatment of neuroendocrine and metastatic prostate cancer. Delivering optimal radiation dose to tumors while minimizing dose to organs-at-risk (OAR) remains an unmet need because of significant patient-to-patient heterogeneity in treatment response, necessitating multiple snapshots of the in vivo activity distribution. Toward this goal, here we present a high temporal resolution activity reconstruction method demonstrated on preclinical prostate cancer models.